Table 1.

Patient Demographics, Tumor Clinicopathologic Features and Genetic Characteristics of Patients with Circulating Tumor Cells based upon ALDH staining

Variable	All patients (n=60) (%)	ALDH-positive CTCs (n=46)	Absence of ALDH-positive CTCs (n=14)	P-Value
Average Age (range) (years)	64.6 (27–88)	65.3 (27–88)	63.4 (40–86)	0.42
Gender
Male	37 (62%)	29 (63%)	8 (57%)	0.76
Female	23 (38%)	17 (37%)	6 (24%)
Average CA19-9	612 (0.6–9032)	711 (0.6–9032)	242 (1–1031)	0.16
CA 19-9 Level (n=46)				0.43
High (> 36)	28 (61%)	23 (64%)	5 (50%)
Low (< 36)	18 (39%)	13 (36%)	5 (50%)
Surgical Resection
Whipple	44 (73%)	33 (72%)	11 (79%)	0.87
Distal pancreatectomy	12 (20%)	10 (22%)	2 (14%)
Total pancreatectomy	4 (7%)	3 (6%)	1 (7%)
Average Tumor Size (range) (cm)	3.2 (0.1 – 8)	3.2 (0.1–8)	3.1 (0.1–6)	0.85
Tumor Grade
Well	3 (5%)	3 (7%)	0 (0%)	>0.99
Moderate	31 (52%)	23 (50%)	8 (57%)
Poor	25 (41%)	19 (41%)	6 (43%)
Not specified	1 (2%)	1 (2%)	0 (0%)
Positive lymph nodes	42 (70%)	31 (67%)	11 (79%)	0.52
Positive margin	12 (20%)	9 (20%)	3 (21%)	> 0.99
Stage
Stage I	12 (20%)	10 (22%)	2 (14%)	0.39
Stage II	46 (76%)	35 (76%)	11 (79%)
Stage III	1 (2%)	0 (0%)	1 (7%)
Stage IV	1 (2%)	1 (2%)	0 (0%)
Perineural invasion	47 (78%)	36 (78%)	11 (79%)	0.99
Perivascular invasion	40 (67%)	31 (67%)	9 (64%)	>0.99
Neoadjuvant Chemotherapy	24 (40%)	19 (41%)	5 (36%)	0.77
Adjuvant Chemotherapy	52 (91%)	40 (89%)	12 (100%)	0.57
Average Percent Cells Staining with ALDH	50% (<5–100%)	50% (<5–100%)	60% (20–90%)	0.59
Primary tumor ALDH Staining - Intensity				0.55
Weak	9 (15%)	6 (13%)	3 (21%)
Moderate	34 (57%)	27 (59%)	7 (50%)
Strong	17 (28%)	13 (28%)	4 (29%)
ALDH staining as intense as controls (n=57)				0.52
Yes	24 (42%)	20 (45%)	4 (31%)
No	33 (58%)	24 (55%)	9 (69%)